Navigation Links
Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
Date:5/21/2013

REDWOOD CITY, Calif., May 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line data demonstrating that in a placebo-controlled Phase 3 study of its investigational sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System (NanoTab System), the primary efficacy endpoint was achieved.  The study evaluated control of pain intensity compared to baseline during the 48-hour study period immediately following major orthopedic surgery, specifically knee or hip replacement, using the FDA-requested primary endpoint of Summed Pain Intensity Difference to baseline (i.e. SPID-48).  Results demonstrated that patients receiving sufentanil NanoTabs realized a significantly greater SPID-48 during the study period than placebo-treated patients (+76.1 vs -11.5, p<0.001).  Secondary endpoint data  showed that SPID at 24 hours and 72 hours was also significantly greater in the sufentanil-treated patients than in the placebo-treated patients (p<0.001 in each case).
Adverse events reported in the study were generally mild or moderate in nature and were similar in both placebo and treatment groups for the majority of adverse events.

"With the successful completion of this study, AcelRx has now achieved positive results in all three Phase 3 studies in which the Sufentanil NanoTab PCA System has been evaluated," said Richard King , president and CEO of AcelRx.  "We remain on track for a third quarter 2013 NDA submission for the NanoTab System, a product which, if approved, will present AcelRx with an opportunity to fundamentally redefine the management of post-operative pain for tens of millions of
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
2. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
3. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
4. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
5. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
6. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
7. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
8. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
9. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
10. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
11. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ... lenses and delivery systems for the eye today reported ... of $20.0 million, a 10% increase over $18.2 million ... constant currency basis, revenues grew 11% during the second ... 2013.  The effect of foreign currency exchange reduced sales ...
(Date:7/31/2014)... (NYSE: RMD ) today announced results for its ... 2014.  Revenue for the quarter was $415.2 million, flat compared ... decrease on a constant currency basis). Net income was $87.7 ... ended June 30, 2013. Diluted earnings per share for the ... the quarter ended June 30, 2013.  The ...
(Date:7/31/2014)... -- Xencor Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... for the second quarter ended June 30, 2014 and ... "In the second quarter, we presented preclinical ... Conference (ATS) demonstrating three novel mechanisms of action ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
... Radial Strength, FlexibilityHOUSTON, March 18 IDEV Technologies ... and marketing of minimally invasive technologies, announced today ... has approved an investigational device exemption (IDE) for ... a novel stent platform designed for the treatment ...
... March 18 ULURU Inc. (NYSE Alternext: ULU) ... diabetic foot ulcers, and data on the use of ... presented at the annual DFCon Global Meeting in Los ... presented on posters that will be on display during ...
Cached Medicine Technology:U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 3
(Date:8/1/2014)... Did you know that July was Sarcoma ... to raise awareness across the country and to educate people ... to the American Cancer Society, nearly 5,000 Americans are expected ... soft tissue sarcomas will be diagnosed. , “A lot ... are other kinds of cancer,” said Dr. Chawla, a physician ...
(Date:8/1/2014)... “When insulation goes bad,” Clean Crawls says, ... a newly released article entitled, “ 5 Signs That ... Replaced ,” Clean Crawls explains the need to replace ... by critters. , Get a free attic insulation ... http://www.cleancrawl.com/contact . , If crawl space or attic ...
(Date:8/1/2014)... 01, 2014 According to the Metabolic Switch ... comprehensive diet guide for women who want to lose weight ... protein rich foods and fat loss fruits that ... , Vkool writes in its review that this book is ... about fat burning hormones and weight loss supplements. , ...
(Date:8/1/2014)... The Multiple System Atrophy Coalition, a growing nonprofit 501 ... affected by the neurological disorder Multiple System Atrophy (MSA), announced ... to its Board of Directors. , Sharon was the primary ... was diagnosed officially with MSA in 2010 and passed away ... many others with this rare disorder it took several years ...
(Date:8/1/2014)... Blindness is a reversible ailment these days . ... despite well-meaning efforts, still have a long way to go ... blindness that does not involve any kind of health risk ... takes the “slack” from the mainstream by providing a cure ... , Alternative health specialist Kevin Richardson actually has the ...
Breaking Medicine News(10 mins):Health News:July Was Sarcoma Awareness Month! 2Health News:July Was Sarcoma Awareness Month! 3Health News:July Was Sarcoma Awareness Month! 4Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2
... that allows products to be traced through the U.S. supply chain might have helped contain the ... announced today. iGPS urged the U.S. Senate to mandate the latest tracking technology in legislation pending ... ... ...
... study recently published in Academic Emergency Medicine ... older to receive potentially inappropriate medications when treated in ... or 16.8 percent of eligible emergency visits from 2000-2006, ... PIMs. The large sample of approximately 470,000 ED and ...
... to their normal state of mind soon after they get ... No matter how cheerful you felt as you wiggled your ... how thrilled you were to finally lay eyes on that ... new research shows the happiness boost many experience while vacationing ...
... Dr. ... and Boca Raton, Florida. These sites provide important information on emergency services, treatments, and offer ... ... launched a new web site designed to reach more patients in Boca Raton. The ...
... March 12 O.N.E., One Natural Experience debuts ... water that goes the extra mile.  O.N.E. Active provides the ... the #1 selling super-hydrator, O.N.E. Coconut Water -- but with ... provides the added edge of sharpening the mind while engaging ...
... More players had ligament damage, ankle sprains than on ... News) -- Pro football players are more likely to ... an artificial turf called FieldTurf than on natural grass, ... the 2002-2008 National Football League seasons and found that ...
Cached Medicine News:Health News:Massive Food Flavoring Recall Underscores Need for New Tracking Technology to Contain Outbreaks of Foodborne Illness 2Health News:Massive Food Flavoring Recall Underscores Need for New Tracking Technology to Contain Outbreaks of Foodborne Illness 3Health News:Massive Food Flavoring Recall Underscores Need for New Tracking Technology to Contain Outbreaks of Foodborne Illness 4Health News:Massive Food Flavoring Recall Underscores Need for New Tracking Technology to Contain Outbreaks of Foodborne Illness 5Health News:Some older ER patients are getting the wrong medicines, U-M study finds 2Health News:Happy From Your Vacation? It Won't Last 2Health News:Happy From Your Vacation? It Won't Last 3Health News:Delray Beach and Boca Raton Veterinarian Launches New Web Sites for Atlantic Animal Hospital 2Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 2Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 3Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 4Health News:Football Injuries More Likely on Certain Artificial Turf 2
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
... bright xenon illumination for ... other instruments. Port allows ... optic cables. Worldwide voltage ... lamp change drawer ...
Medicine Products: